Hiro Tatetsu

883 total citations
35 papers, 600 citations indexed

About

Hiro Tatetsu is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Hiro Tatetsu has authored 35 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Hematology and 8 papers in Genetics. Recurrent topics in Hiro Tatetsu's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Hiro Tatetsu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Hiro Tatetsu collaborates with scholars based in Japan, United States and Singapore. Hiro Tatetsu's co-authors include Hiroaki Mitsuya, Daniel G. Tenen, Yutaka Okuno, Li Chai, Chong Gao, Hiroyuki Hata, Shikiko Ueno, Giovanni Amabile, Nikki R. Kong and Miki Nakamura and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Hiro Tatetsu

32 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiro Tatetsu Japan 15 356 127 125 123 119 35 600
Michiaki Koike Japan 12 187 0.5× 178 1.4× 150 1.2× 100 0.8× 100 0.8× 48 509
Sharmila Mallya United States 12 495 1.4× 138 1.1× 53 0.4× 108 0.9× 133 1.1× 20 656
Christian Hurtz United States 10 246 0.7× 258 2.0× 47 0.4× 107 0.9× 151 1.3× 32 607
Anand Jillella United States 12 456 1.3× 379 3.0× 59 0.5× 113 0.9× 136 1.1× 48 841
Soumen Chakraborty India 13 434 1.2× 197 1.6× 60 0.5× 60 0.5× 88 0.7× 27 635
Luigia Monitillo Italy 8 134 0.4× 151 1.2× 145 1.2× 112 0.9× 44 0.4× 16 497
Yingzhe Yu China 9 195 0.5× 195 1.5× 79 0.6× 117 1.0× 215 1.8× 23 626
Swapna Thota United States 11 269 0.8× 328 2.6× 103 0.8× 141 1.1× 116 1.0× 55 621
M Allouche France 12 303 0.9× 141 1.1× 46 0.4× 67 0.5× 118 1.0× 25 583
Haerim Chung South Korea 12 123 0.3× 122 1.0× 81 0.6× 62 0.5× 73 0.6× 46 352

Countries citing papers authored by Hiro Tatetsu

Since Specialization
Citations

This map shows the geographic impact of Hiro Tatetsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiro Tatetsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiro Tatetsu more than expected).

Fields of papers citing papers by Hiro Tatetsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiro Tatetsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiro Tatetsu. The network helps show where Hiro Tatetsu may publish in the future.

Co-authorship network of co-authors of Hiro Tatetsu

This figure shows the co-authorship network connecting the top 25 collaborators of Hiro Tatetsu. A scholar is included among the top collaborators of Hiro Tatetsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiro Tatetsu. Hiro Tatetsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tatetsu, Hiro, Yusuke Higuchi, Toshikazu Miyakawa, et al.. (2025). Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma. British Journal of Haematology. 208(1). 159–169.
2.
Tatetsu, Hiro, Koji Kato, Atsushi Wada, et al.. (2025). Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. International Journal of Hematology. 122(6). 815–819.
3.
Sekiguchi, Naohiro, Shinya Rai, Wataru Munakata, et al.. (2022). Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia. Cancer Science. 113(6). 2085–2096. 22 indexed citations
4.
Tatetsu, Hiro, Kisato Nosaka, Yusuke Higuchi, et al.. (2022). Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma. SHILAP Revista de lepidopterología. 3(2). 385–393. 2 indexed citations
5.
Nishikori, Momoko, Kimikazu Yakushijin, Shingo Kurahashi, et al.. (2022). Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. International Journal of Hematology. 115(3). 382–390. 5 indexed citations
6.
Tatetsu, Hiro, Kisato Nosaka, Kennosuke Karube, et al.. (2022). [Follicular T-cell lymphoma successfully treated with long-term corticosteroid].. PubMed. 63(11). 1497–1502. 1 indexed citations
7.
Tatetsu, Hiro, Daniel G. Tenen, & Li Chai. (2021). The Interplay between Transcription Factor SALL4 and Histone Modifiers in Hematopoietic Stem and Progenitor Cells. PubMed. 3(1). 26–30. 1 indexed citations
8.
Sekiguchi, Naohiro, Shinya Rai, Wataru Munakata, et al.. (2020). A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia. Cancer Science. 111(9). 3327–3337. 60 indexed citations
9.
Tatetsu, Hiro, Myriam Armant, Fei Wang, et al.. (2019). Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology. 75. 53–63.e11. 4 indexed citations
10.
Nishimura, Nao, Mohamed O. Radwan, Masayuki Amano, et al.. (2019). Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells. Cancer Science. 110(10). 3275–3287. 26 indexed citations
11.
Endo, Shinya, Nao Nishimura, Yawara Kawano, et al.. (2018). MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells. Biochemical and Biophysical Research Communications. 507(1-4). 246–252. 6 indexed citations
12.
Nishimura, Nao, Shinya Endo, Shikiko Ueno, et al.. (2017). A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo. Biochemical and Biophysical Research Communications. 486(4). 916–922. 2 indexed citations
13.
Nishimura, Nao, Shikiko Ueno, Shinya Endo, et al.. (2017). PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. Oncogene. 36(31). 4481–4497. 27 indexed citations
14.
Tatetsu, Hiro, Nikki R. Kong, Chong Gao, et al.. (2016). SALL4, the missing link between stem cells, development and cancer. Gene. 584(2). 111–119. 86 indexed citations
15.
Okuno, Yutaka, Hiro Tatetsu, Kisato Nosaka, & Hiroaki Mitsuya. (2012). Three Cases of Aggressive Natural Killer Cell Leukemia with a Lethal Hemorrhagic Complication. Journal of Clinical and Experimental Hematopathology. 52(2). 101–106. 5 indexed citations
16.
Uchiba, Mitsuhiro, Takahisa Imamura, Hiroyuki Hata, et al.. (2009). Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid. 16(2). 89–93. 17 indexed citations
17.
Hatakeyama, Kinta, Takashi Sonoki, Hiro Tatetsu, et al.. (2009). Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients. International Journal of Hematology. 90(2). 217–225. 3 indexed citations
18.
Tatetsu, Hiro, Shikiko Ueno, Hiroyuki Hata, et al.. (2007). Down-regulation of PU.1 by Methylation of Distal Regulatory Elements and the Promoter Is Required for Myeloma Cell Growth. Cancer Research. 67(11). 5328–5336. 41 indexed citations
19.
Nakamura, Miki, Tomomi Gotoh, Yutaka Okuno, et al.. (2006). Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leukemia & lymphoma. 47(3). 531–539. 55 indexed citations
20.
Tatetsu, Hiro, Norio Asou, Miki Nakamura, et al.. (2006). Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. American Journal of Hematology. 81(5). 366–369. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michiaki Koike Breakdown of academic impact, for papers by Sharmila Mallya Breakdown of academic impact, for papers by Christian Hurtz Breakdown of academic impact, for papers by Anand Jillella Breakdown of academic impact, for papers by Soumen Chakraborty Breakdown of academic impact, for papers by Luigia Monitillo Breakdown of academic impact, for papers by Yingzhe Yu Breakdown of academic impact, for papers by Swapna Thota Breakdown of academic impact, for papers by M Allouche Breakdown of academic impact, for papers by Haerim Chung
Rankless by CCL
2026